These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1118 related items for PubMed ID: 25051423

  • 1. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 3. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Sep; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
    Aldè M, Ambrosetti U, Giuditta M, Cassinerio E, Piatti G.
    Auris Nasus Larynx; 2024 Apr; 51(2):271-275. PubMed ID: 37903661
    [Abstract] [Full Text] [Related]

  • 10. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 11. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Dec; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 12. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Dec; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 13. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V, Kurtoglu E.
    Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
    [Abstract] [Full Text] [Related]

  • 14. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ.
    Hemoglobin; 2006 Jan; 30(2):329-47. PubMed ID: 16798657
    [Abstract] [Full Text] [Related]

  • 15. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Jan; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 16. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 17. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Oct; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 18. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Oct; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 20. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Nov; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.